Hims & Hers Charts a Global Course with Major Acquisition

Hims & Hers expands globally with a $1.15B deal for Eucalyptus, aiming to reduce U.S. reliance after regulatory challenges and a legal settlement boosted its stock.

In a strategic pivot designed to reduce its reliance on a turbulent U.S. market, the telehealth company Hims & Hers is embarking on a significant international expansion. The catalyst for this shift is a planned acquisition of the Australian digital health platform Eucalyptus for up to $1.15 billion.

A Strategic Response to Domestic Headwinds

The timing of this overseas move is directly linked to recent regulatory challenges at home. In the United States, Hims & Hers has faced substantial pressure, including revised rules for shipping personalized metabolic treatments that are expected to impact first-quarter 2026 guidance by $65 million.

Furthermore, the company abandoned plans to market a compounded version of the weight-loss injection Wegovy following a lawsuit from Novo Nordisk. A resolution was reached in early March, with both parties agreeing to a partnership for the direct distribution of the original pharmaceuticals. This settlement triggered a dramatic surge in the stock price, sending shares soaring over 40% on March 9th. Notably, during this period, major shareholder JPMorgan significantly reduced its stake from 8.1% last September to 1.7%.

The $1.15 Billion Expansion Engine

Eucalyptus operates five digital health clinics and serves more than 775,000 customers across Australia, Canada, Germany, and the United Kingdom. The platform, with an annual recurring revenue exceeding $450 million and triple-digit growth, aligns perfectly with Hims & Hers' expansion strategy.

The acquisition will be financed in stages. Approximately $240 million in cash will be paid upon the expected closing in mid-2026. An additional $710 million is structured as guaranteed, deferred payments, supplemented by potential performance-based earnouts of up to $200 million.

This deal accelerates the company's systematic build-out of its international footprint, following previous acquisitions of the European platform Zava and providers in Canada and the United States. Japan is also emerging as a key long-term growth market in management's sights.

Wall Street Recalibrates Its Outlook

The resolution of the legal dispute and the new distribution agreement have prompted a reassessment on Wall Street. Several analyst firms have recently upgraded their ratings and price targets:

• Needham & Company: Upgraded to "Buy" with a $30.00 target.
• Leerink Partners: Raised its price target from $17.50 to $25.00.
• Citigroup: Upgraded to "Neutral" with a $24.00 target.
• Bank of America: Upgraded to "Neutral" with a $23.00 target.

Fundamentally, the company reports a strong base. For the full year 2025, Hims & Hers announced a 59% revenue jump to approximately $2.35 billion, alongside a net profit of $128.4 million.

The Road Ahead: Integration and Regulation

Management remains committed to its long-term vision, targeting $6.5 billion in revenue by 2030. The strategic shift to distributing branded medications is seen as inevitable, especially as FDA shortage lists for these drugs shrink due to ramped-up production from Novo Nordisk and Eli Lilly.

With the integration of Eucalyptus, the primary operational challenge now shifts to the international stage. The company must navigate the diverse healthcare regulations and compliance rules across Europe and Australia to successfully execute its global mission.